ADC Therapeutics

BerGenBio ASA (FRA:7BG0) identified a significant unmet medical need in STK 11 mutated patients, received FDA fast-track designation, and has a strong safety database. However, faced administrative delays, discontinued Sylvest program, and CEO Martin Olin is leaving. Interim BTBC 16 study data expected early 2025, final phase two data as late as 2026.

BerGenBio ASA (FRA:7BG0) reports $40M revenue, $175M cash position, and FDA fast-track designation for STK 11 mutated patients. CEO Martin Olin's departure planned for smooth transition. Interim BTBC 16 study data expected early 2025, final phase two data by 2026. Sylvester program discontinued due to lack of partnerships. Limited news flow between quarterly updates maintained for data-driven transparency.

Stephens analyst initiates coverage on ADC Therapeutics (ADCT), highlighting Zynlonta's potential despite market challenges. The analyst projects Zynlonta's peak revenue at $110 million by 2032 in the third-line setting and $172 million in second-line DLBCL, supported by LOTIS-5 and LOTIS-7 trial results. ADCT's broad ADC pipeline offers additional growth opportunities.

Antibody drug conjugates (ADCs) are a transformative class in cancer treatment, with 16 approved products and sales exceeding $10B in 2023. The market is expected to surpass $50B by 2030, driven by over 500 ADCs in clinical trials. Key players include Enhertu, Kadcyla, and Padcev, with significant sales in breast and lung cancers. The US and China lead the market, supported by robust R&D and regulatory environments.

The article discusses the importance of enabling JavaScript for optimal app performance.

The Cancer Antibody Drug Conjugates Market report highlights the transformative potential of ADCs in cancer treatment, with 16 approved products and sales exceeding $10B in 2023. The market is projected to surpass $50B by 2030, driven by ongoing clinical trials and increased R&D efforts. Key players include Padcev, Kadcyla, and Enhertu, with significant development activity in lung and breast cancer. The market is led by the US and China, with major pharmaceutical companies driving innovation.